IBDoc® Calprotectin Home Test

Setting New Standards in IBD Monitoring
Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as can be seen in many chronic diseases. While treatment options have alleviated the disease burden for many patients in recent years, a large part still experience more than one flare per year (IBD2020 Report, 2013).

In the review article “Improving quality of care in inflammatory bowel disease: what changes can be made today?” Panes et al. conclude that one important element is to empower patients to actively participate in their disease management. A number of prospective studies show that calprotectin correlates well to mucosal healing and histologic inflammation with high sensitivity and specificity (Lobaton et al., 2013; Guardiola et al., 2012). Furthermore calprotectin assays also delivered valuable data on predicting coming relapses within the next 3 months in quiescent Crohn’s Disease (Naismith et al., 2014).

IBDoc® is the first CE-IVD certified fecal Calprotectin home test that is fully designed for remote IBD disease monitoring. IBDoc® uses a reliable and easy to use smartphone-based remote care solution and is the next step to improve the Quality of Care and Quality of Life of IBD patients.

Key Benefits

1. Easy to use for all patients
2. Excellent agreement with Laboratory based Methods
3. Reliable Smartphone Validation process
4. Independently clinically evaluated

Methods Comparison

- Due to a robust and reliable validation procedure, all validated smartphone models show improved correlation with the Point of Care reference assay Quantum Blue® fCAL extended (Figure 1).
- Results performed by patient under the supervision of a trained professional correlate well to the reference result from the trained professional (Figure 2).
- In a real world situation where patients performed IBDoc® at home and sent in a stool sample to be measured via the reference BÜHLMANN fCAL® ELISA, 87% of the results (N=152) were in agreement at a cut-off of 100 µg/g (Figure 3).
Key Benefits for Patients

- **Easy to use**: Patients scored the overall Usability of IBDoc® with 85 points out of 100 on a standardized usability questionnaire (Figure 4) and were 100% satisfied with the solution.

- **Better disease management**: 83% of patients reported that IBDoc® helps them to manage their disease better (Figure 5).

- **Preferred Method**: 85% favored IBDoc® over traditional stool sample collections.

“...IBDoc® is very useful in determining my calprotectin value and it is incredibly easy to use. I think it is extremely convenient!”

    Student & Crohn’s Patient from Vienna

Key Benefits for Health Care Professionals

- **Remote IBD monitoring**: Patients can stay away from clinics for longer periods of time but are still tightly monitored via immediately shared IBDoc® results.

    „There is sufficient agreement between IBDoc® home test and hospital-based ELISA in the lower ranges for calprotectin to use this new test for disease monitoring”

- **Avoiding Hospital Visits**: Treating physicians can keep track of their patients at home and only need to contact them, when calprotectin values are high (Figure 6).

    „IBDoc® has a Negative Predictive Value (NPV) of 88% to predict that patients with a value below 100 µg/g (green) stay in remission during the next 4 months”

---

1. Weber et al., Validation of a smartphone-based patient monitoring system measuring calprotectin, ECCO 2015 Poster
2. Ungar B. et al., P181 Home smart-phone based measurement of fecal calprotectin by IBD patients: correlation with laboratory assay and applicability as patient-friendly monitoring tool, ECCO 2017 Poster
3. Heida A. et al., Agreement Between Home-based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity, Clin Gastroenterology and Hepatology, 2017
4. Bello C. et al., Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients, Digestive and Liver Disease, 2017.
5. Fitzgerald D. et al., N804 An evaluation of patient satisfaction with IBDoc calprotectin home test system, ECCO 2017 Poster
6. Raker J., et al., P599 Home testing for faecal calprotectin: follow-up results from the first UK trial, ECCO 2017 Poster
IBDoc®

Three easy steps to test calprotectin at home

1

2

3

visit us on www.ibdoc.net

CE0123
Health Canada Licence: 98903, Device class: 3
IBDoc® is not available for sale in the US.

Ordering code:
BI-IBDOC IBDoc Starter Kit
LF-IBDOC8 IBDoc Calprotectin Kit (8 tests)

IBDoc®, BÜHLMANN ICAL®, CalApp®, CALEX® and Quantum Blue® are registered trademarks of BÜHLMANN in many countries.

BÜHLMANN Laboratories AG
Baselstrasse 55
4124 Schönenbuch
Switzerland
Phone +41 61 487 12 12
Fax orders +41 61 487 12 99
info@buhlmannlabs.ch
www.buhlmannlabs.ch